Skip to main content

Table 2 Summary of plasma remoglifozin etabonate pharmacokinetic parameters in healthy subjects a,b

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Remogliflozin etabonate dose 20 mg 50 mg 150 mg 500 mg 1000 mg
AUC (0–∞) (ng•h/mL) NQc 3.70 (46)d 9.77 (48)d 36.8 (67)e 126 (44)f
AUC (0–t) (ng.h/mL) 1.61 (67) g 3.56 (56) 9.51 (42) 35.4 (62) 107 (53)
C max (ng/mL) 1.89 (78) 4.98 (61) 17.6 (48) 41.6 (81) 144 (59)
T max (h) 0.625 0.625 0.515 1.25 0.625
0.33-2.03 0.17-1.50 0.17-1.50 0.33-2.50 0.33-2.50
T ½ (h) NQc 0.353 (56)d 0.256 (35)d 0.263e (27) 0.707f (56)
  1. a. Geometric mean and CV% except for Tmax (median and range).
  2. b. n = 8 unless otherwise specified.
  3. c. NQ, not quantifiable because concentrations at later time points were below the limit of quantification.
  4. d. n = 6.
  5. e. n = 4.
  6. f. n = 7.
  7. g. n = 5.